Enterprise Planning
Our enterprise planning practice leverages our
biomedical-specific process expertise to deliver enterprise
and program plans that are immediately implementable, tightly
executable, and focused on important milestones.
Representative context of our enterprise and
program planning engagements includes:
- Integration of programs from partnering,
strategic alliances, and licensing activities
- New enterprise and program formations
that target high-value business spaces
- Strategic, operational, and financial
planning and budgeting
- Restructurings, including mergers,
acquisitions, joint ventures, spin-offs, and equity carve-outs
- Equity investments, asset purchases,
and management buyouts
Representative scope of our enterprise and program
planning engagements can include:
- Multiphase planning, from initial order-of-magnitude
milestones, budgets, and timelines through precise, internally-benchmarked,
and vendor/FDA-validated projections
- Key enterprise and program milestone
identification
- Technology, clinical, and market environment
forecasting and analysis, as needed
- Clinical and preclinical development
plan milestone identification, technology risk assessment,
budgeting, and timeline estimation
- FDA approval pathway identification,
approvability assessment, and timeline estimation
- Product/procedure coding, reimbursement,
and purchasing plan milestone identification, budgeting,
and timeline estimation
- Manufacturing scale-up and GMP/QSR/standards
compliance assessment, budgeting, and timeline estimation
- Intellectual property milestone identification,
budgeting, and timeline estimation
- Implementation risk evaluation with
in-depth, confidential interviews among senior industry
executives from all key vertical industry sectors
- Pro forma program and enterprise financial
modeling, including forecasts of enterprise earnings, earnings
dilution, and cash flow
- Multi-scenario equity and debt-financed
capital structure and balance sheet forecasting
- State-of-the-art modeling of shareholder
value employing discounted cash flow (including program
IRR and firm FCFF), real options (including compound and
switching options), and comparable (including milestone-based)
methodologies
|
